332 related articles for article (PubMed ID: 30920845)
1. TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling.
Duan HX; Li BW; Zhuang X; Wang LT; Cao Q; Tan LH; Qu GF; Xiao S
Am J Physiol Gastrointest Liver Physiol; 2019 Jun; 316(6):G763-G773. PubMed ID: 30920845
[TBL] [Abstract][Full Text] [Related]
2. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G
Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085
[TBL] [Abstract][Full Text] [Related]
3. Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT.
Zhang Y; Ji G; Han S; Shao Z; Lu Z; Huo L; Zhang J; Yang R; Feng Q; Shen H; Wang H; Li X
Cell Physiol Biochem; 2018; 50(2):612-628. PubMed ID: 30308494
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
5. Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6/STAT3/VEGFA signaling pathway.
Leng K; Xu Y; Kang P; Qin W; Cai H; Wang H; Ji D; Jiang X; Li J; Li Z; Huang L; Zhong X; Sun X; Wang Z; Cui Y
Cell Death Dis; 2019 Mar; 10(4):262. PubMed ID: 30886152
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
[TBL] [Abstract][Full Text] [Related]
7. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
Huang M; Huang B; Li G; Zeng S
BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
[TBL] [Abstract][Full Text] [Related]
8. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
[TBL] [Abstract][Full Text] [Related]
9. Silencing of LAMC2 Reverses Epithelial-Mesenchymal Transition and Inhibits Angiogenesis in Cholangiocarcinoma via Inactivation of the Epidermal Growth Factor Receptor Signaling Pathway.
Pei YF; Liu J; Cheng J; Wu WD; Liu XQ
Am J Pathol; 2019 Aug; 189(8):1637-1653. PubMed ID: 31345467
[TBL] [Abstract][Full Text] [Related]
10. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
Dokduang H; Juntana S; Techasen A; Namwat N; Yongvanit P; Khuntikeo N; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3519-28. PubMed ID: 23812726
[TBL] [Abstract][Full Text] [Related]
11. Cordycepin Inhibits Cancer Cell Proliferation and Angiogenesis through a DEK Interaction via ERK Signaling in Cholangiocarcinoma.
Liu T; Zhu G; Yan W; Lv Y; Wang X; Jin G; Cui M; Lin Z; Ren X
J Pharmacol Exp Ther; 2020 May; 373(2):279-289. PubMed ID: 32102917
[TBL] [Abstract][Full Text] [Related]
12. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
14. The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma.
Peng T; Deng X; Tian F; Li Z; Jiang P; Zhao X; Chen G; Chen Y; Zheng P; Li D; Wang S
Int J Oncol; 2019 Sep; 55(3):657-670. PubMed ID: 31322171
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
16. TCF21 inhibits proliferation and chemoresistance through the AKT pathway in human gastric cancer.
Yang Z; Jiang X; Li D; Dong Q; Zhao H; Jiang X
Gene; 2019 Jan; 682():42-49. PubMed ID: 30296564
[TBL] [Abstract][Full Text] [Related]
17. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo.
Xu D; Ma Y; Zhao B; Li S; Zhang Y; Pan S; Wu Y; Wang J; Wang D; Pan H; Liu L; Jiang H
Oncol Rep; 2014 May; 31(5):2063-70. PubMed ID: 24603952
[TBL] [Abstract][Full Text] [Related]
19. CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion.
Dana P; Saisomboon S; Kariya R; Okada S; Obchoei S; Sawanyawisuth K; Wongkham C; Pairojkul C; Wongkham S; Vaeteewoottacharn K
Cell Oncol (Dordr); 2020 Apr; 43(2):211-222. PubMed ID: 31729681
[TBL] [Abstract][Full Text] [Related]
20. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
